Myasthenia Gravis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 19 and 74 years old
- You have been diagnosed with Myasthenia Gravis (MG) that affects only the eye muscles (causing drooping eyelids or double vision, but no other symptoms), and you have never received treatment for it
- Your diagnosis is supported by at least one of the following: your symptoms responded clearly to a medication called pyridostigmine; a blood test showed certain MG-related antibodies; a nerve stimulation test showed a significant drop in muscle response; or a special muscle electrical test showed abnormal results
- You are willing to provide samples (such as blood), undergo scans, and take part in other tests related to the study
- If you are a woman who could become pregnant, you had a negative pregnancy test before the study and you and your partner agree to use effective contraception throughout the study
- You are willing to give written consent to take part
- Your expected survival is longer than 3 years
Who may not be able to join:
- You have another long-term, psychiatric, or neurological condition (other than MG) that causes weakness or tiredness
- You have another condition that could explain your drooping eyelids, double vision, or muscle weakness
- You are 18 years old or younger, or 75 years old or older
- You are already taking steroid or immune-suppressing medications for another immune system condition
- You have another chronic illness that means you cannot safely take immune-suppressing medications
- You have a severe mental illness or memory/thinking problems that would make it difficult to attend follow-up appointments or complete self-assessments
- You are pregnant, breastfeeding, or planning to become pregnant during the trial
- You have had a serious infection or cancer in the last month that means you cannot take immune-suppressing medications
- You are not willing to undergo repeat nerve stimulation tests or chest CT scans
- You are not willing to take part in the study
- You are unable to sign a consent form
- Your expected survival is less than 3 years
- The research team has assessed you as unsuitable for other reasons (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jun Guo, Tangdu Hospital, Air Force Military Medical University
Phone: 86-29-8477 8844
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Conversion rate from ocular to generalized MG at the last follow-up visit.; Changes in the ratio of patients who achieve the level 2 of MG Status and Treatment Intensity (MGSTI) scale or better.; Changes in proportion of patients with treatment-related adverse events.; Changes in scores of Quantitative Myasthenia Gravis (QMG) scale and of Absolute and Relative Score of MG(ARS-MG) scales from Baseline.; Changes in scores of MG-specific Activities of Daily Living (MG-ADL) scale from Baseline.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.